Key Insights on Gross Profit: Exelixis, Inc. vs Alkermes plc

A Decade of Growth: Exelixis, Inc. vs Alkermes plc

In the competitive landscape of biotechnology, Exelixis, Inc. and Alkermes plc have showcased remarkable growth in gross profit over the past decade. From 2014 to 2023, Exelixis, Inc. has seen an impressive increase, with its gross profit surging by over 7,500%, reaching approximately $1.76 billion in 2023. This growth trajectory highlights Exelixis's strategic advancements and market positioning.

Conversely, Alkermes plc, while not as explosive, has demonstrated steady growth, with its gross profit increasing by over 700% during the same period, culminating in around $1.41 billion in 2023. This consistent performance underscores Alkermes's resilience and adaptability in a rapidly evolving industry.

The data reveals a compelling narrative of two companies navigating the biotech sector's challenges and opportunities, each carving out a distinct path to profitability.